title: Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.
authors.affiliation: Department of Neurology, University of Leipzig, Liebigstraße 20, 04103, Leipzig, Germany.
authors.forename: Muriel
authors.initials: M
authors.lastname: Stoppe
authors.forename: Eva
authors.initials: E
authors.lastname: Thomä
authors.forename: Uwe Gerd
authors.initials: UG
authors.lastname: Liebert
authors.forename: Eugene O
authors.initials: EO
authors.lastname: Major
authors.forename: Karl-Titus
authors.initials: KT
authors.lastname: Hoffmann
authors.forename: Joseph
authors.initials: J
authors.lastname: Claßen
authors.forename: Florian
authors.initials: F
authors.lastname: Then Bergh
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002531:Cerebellum / Q000187:drug effects* / Q000473:pathology / Q000821:virology; D000069462:Dimethyl Fumarate; D005650:Fumarates / Q000009:adverse effects*; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005650:Fumarates; D000069462:Dimethyl Fumarate; C472181:efalizumab